XML 25 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies (Details 4) (USD $)
12 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Apr. 01, 2007
Patents      
Accumulated amortization $ (190,770) $ (169,084)  
Total net patents and patent applications 237,606 272,714  
Other Accrued Liabilities      
Warranty 55,000 65,000  
Sales commissions 29,492 51,417  
Lease normalization 36,610 44,249  
Sales and use tax 37,460 43,137  
Marketing fees 10,279 12,183  
Insurance   28,875  
Legal and audit fees 31,426 9,701  
Payroll taxes 25,932    
Medical device tax 63,808    
Employment agreement 123,980 118,408  
Miscellaneous 32,184 (23,834)  
Total other accrued liabilities 446,171 349,136  
Income Taxes      
ASC 740 liability 0    
Unrecognized tax benefits 0   0
Amount of income tax related interest or penalties assessed or recorded 0    
Impact on effective tax rate due to adoption of ASC 740 0.00%    
Sales Recognition      
Obligations related to product sales 0    
Medical Device Tax      
Excise tax rate on the sale of certain medical devices (as a percent) 2.30%    
Patents
     
Patents      
Economic or legal life 20 years    
Patents issued 243,721 215,801  
Accumulated amortization (190,770) (169,084)  
Patents issued, net of accumulated amortization 52,951 46,717  
Patent applications 184,655 225,997  
Total net patents and patent applications 237,606 272,714  
Expected annual amortization expense related to patents and patent applications      
2014 19,356    
2015 19,106    
2016 18,414    
2017 18,183    
2018 and following 162,547    
Total $ 237,606